Patent · US Active

Five-membered heterocyclic amides WNT pathway inhibitor

US10821104B2 · kind B2 · utility

0Cited by

0References

9Claims

0Family size

Assignee

SUZHOU SINOVENT PHARMACEUTICALS CO., LTD. · CN

Inventors

Yonghui Wang · Collegeville, US
Yan Zhu · Beijing, CN
Juan Zhou · Zhejiang, CN
Yujun Gao · Zhejiang, CN
Shiqun Wang · Zhejiang, CN
Dong Wang · Hefei, CN
Wandeng Liu · Zhejiang, CN
Ximing Shen · Zhejiang, CN
Binbin Hong · Zhejiang, CN
Tao Liu · Shanghai, CN
Yaodong Wu · Zhejiang, CN
Chunqi Li · Zhejiang, CN

Key dates

Filing date	Dec 7, 2016
Grant date	Nov 3, 2020
Priority date	—
Expiry date	Dec 7, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A five-membered heterocyclic amide WNT pathway inhibitor having the following general structural formula: The five-membered heterocyclic amide WNT pathway inhibitor has a remarkable anti-tumor activity based on a target-based rational drug design, and can be used for the development of a new generation of Wnt pathway inhibitors, and has a great clinical application value and considerable market potential.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.